Carcinogenesis Advance Access published online on October 14, 2004
Carcinogenesis, doi:10.1093/carcin/bgh310
© 2004 by Oxford University Press
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Pathology, University of Pittsburgh, School of Medicine, 3550 Terrace Street, Pittsburgh, Pennsylvania 15261
* To whom correspondence should be addressed. E-mail: luoj{at}msx.upmc.edu.
Recent work using high-throughput microarray technology has discovered altered expression of a large number of genes in prostate cancer. Many of these alterations may be the consequence of the changes in methylation status in the CpG islands of promoter or exon 1 regions of these genes. In order to screen the methylation status of large number of genes and ESTs, we combined the principle of match/mismatch hybridization with the techniques of whole genome labeling to develop a highly specific oligonucleotide based methylation microarray. Using this array, we analyzed the methylation status of 105 genes and ESTs in three prostate cancer cell lines. Thirty-two to 47% of these genes and ESTs were methylated in these cell lines. By correlating the methylation status of this array with the results of Affymetrix expression arrays of three prostate cancer cell lines, we determined that methylation of genes played a significant role (37%) in down regulating certain gene expression in prostate cancer. We also tested this array on a number of primary prostate tissue samples. Our results indicated that a subset of genes in this microarray (25/105) were methylated throughout all prostate cancer samples but not in normal prostate, suggesting potential significance of alterations in methylation status of certain genes in developing prostate cancer.
Revised October 1, 2004
Accepted October 5, 2004
CARCINOGENESIS
High throughput screening of methylation status of genes in prostate cancer using oligonucleotide methylation array
2 Department of Urology, University of Pittsburgh, School of Medicine, 3550 Terrace Street, Pittsburgh, Pennsylvania 15261
![]()
Abstract ![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
S. Yamashita, S. Takahashi, N. McDonell, N. Watanabe, T. Niwa, K. Hosoya, Y. Tsujino, T. Shirai, and T. Ushijima Methylation Silencing of Transforming Growth Factor-{beta} Receptor Type II in Rat Prostate Cancers Cancer Res., April 1, 2008; 68(7): 2112 - 2121. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. P. Yu, G. Yu, G. Tseng, K. Cieply, J. Nelson, M. Defrances, R. Zarnegar, G. Michalopoulos, and J.-H. Luo Glutathione Peroxidase 3, Deleted or Methylated in Prostate Cancer, Suppresses Prostate Cancer Growth and Metastasis Cancer Res., September 1, 2007; 67(17): 8043 - 8050. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. S. Zorn, K. J. Wojno, M. T. McCabe, R. Kuefer, J. E. Gschwend, and M. L. Day 5-Aza-2'-Deoxycytidine Delays Androgen-Independent Disease and Improves Survival in the Transgenic Adenocarcinoma of the Mouse Prostate Mouse Model of Prostate Cancer Clin. Cancer Res., April 1, 2007; 13(7): 2136 - 2143. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. T. McCabe, J. A. Low, S. Daignault, M. J. Imperiale, K. J. Wojno, and M. L. Day Inhibition of DNA Methyltransferase Activity Prevents Tumorigenesis in a Mouse Model of Prostate Cancer Cancer Res., January 1, 2006; 66(1): 385 - 392. [Abstract] [Full Text] [PDF] |
||||

